ENO1 Protein
Overview <table class="infobox infobox-protein">Protein Name </td>Gene Symbol </td>UniProt ID </td>Ensembl ID </td>PDB ID </td>Molecular Weight </td>Protein Length </td>Cellular Location </td>Tissue Expression </td>Protein Family </td>
...
ENO1 Protein
Overview <table class="infobox infobox-protein">Protein Name </td>Gene Symbol </td>UniProt ID </td>Ensembl ID </td>PDB ID </td>Molecular Weight </td>Protein Length </td>Cellular Location </td>Tissue Expression </td>Protein Family </td>
Eno1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction ENO1 (Alpha-Enolase) is a multifunctional glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. Beyond its well-established role in energy metabolism, ENO1 has diverse functions including cell surface plasminogen binding, stress response, and transcriptional regulation. ENO1 has been increasingly implicated in neurodegeneration, with autoantibodies against ENO1 detected in Alzheimer's Disease (AD) and other autoimmune conditions. The protein is 433 amino acids in length with a molecular weight of ~47 kDa. [@palmfeldt2008]
Protein Structure ENO1 has a characteristic enolase fold:
N-terminal domain (residues 1-140): Dimerization interface and structural elementsC-terminal domain (residues 141-433): Contains the enolase active siteMg²⁺ binding sites : Two magnesium ions required for catalytic activityPyridoxal 5'-phosphate binding site : Catalytic lysine residueSurface plasminogen-binding motif : C-terminal Lysine residue for plasminogen bindingInternal linker : Flexible connection between domainsThe active enzyme forms a homodimer.
Normal Function
Glycolytic Enzyme
Catalyzes : 2-phosphoglycerate → phosphoenolpyruvate + H₂OStep 9 of glycolysis : Third ATP-generating stepCritical for cellular energy production High activity in high-energy demand tissues Cell Surface Functions
Plasminogen receptor : Facilitates plasmin generation at cell surfaceCell migration : Involved in cell motility and invasionImmune response : May participate in immune cell functionStress Response
Hypoxia-inducible : Upregulated under hypoxic conditionsOxidative stress : Induced by [reactive oxygen species](/entities/reactive-oxygen-species)Heat shock protein function : Molecular chaperone activityTranscriptional Regulation
c-Myc binding protein : Modulates Myc transcriptional activityNuclear localization : Can function as transcriptional repressorRole in Neurodegeneration
Alzheimer's Disease ENO1 involvement in AD is significant:
Autoantibodies against ENO1 detected in AD patients (PMID:19074618 )Reduced ENO1 activity in AD brain, particularly in [hippocampus](/brain-regions/hippocampus)Oxidative modification of ENO1 impairs functionPlasmin generation : May influence [Aβ](/proteins/amyloid-beta) degradationStress response dysfunction : Impaired neuroprotective responsesPotential biomarker for AD diagnosis
Parkinson's Disease
Elevated ENO1 in CSF of PD patientsPossible biomarker for disease progressionMay be involved in Lewy body formation
Multiple Sclerosis
ENO1 autoantibodies associated with disease activityImmune-mediated destruction of oligodendrocytesIschemic Stroke
ENO1 released after ischemic injury
May serve as damage marker
Frontotemporal Dementia
Altered ENO1 expression in FTLD
Interaction Network ENO1 interacts with:
PGK1 : Upstream glycolytic enzymePKM : Pyruvate kinase (downstream glycolytic enzyme)GAPDH : Glyeraldehyde-3-phosphate dehydrogenasePlasminogen : Cell surface bindingc-Myc : Transcriptional interactionHSP90 : Chaperone complexTPI1 : Triose phosphate isomeraseTherapeutic Implications
Biomarkers
ENO1 autoantibodies as diagnostic markers
CSF ENO1 as progression marker
Therapeutic Targets
Plasminogen activation : Modulating neuroinflammationAntioxidant strategies : Protecting ENO1 from oxidative damageAutoantibody targeting : Immunomodulatory approachesSee Also
[ENO1 Gene](/genes/eno1)
[Glycolysis Pathway](/mechanisms/glycolysis)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Autoimmunity in Neurodegeneration](/mechanisms/autoimmunity-neurodegeneration)
[Oxidative Stress](/mechanisms/oxidative-stress)
[Biomarkers](/biomarkers)
Overview Eno1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background The study of Eno1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[UniProt: ENO1](https://www.uniprot.org/uniprot/P06733)
[Ensembl: ENO1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143894)
[GeneCards: ENO1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ENO1)
[PDB: ENO1](https://www.wwpdb.org/pdb/3B97)
References
[Butterfield DA, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/19074618/)
[Palmfeldt J, et al, (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18317678/)
[Haque A, et al, (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15165678/)
[Zheng JY, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23562889/)
[Zhan R, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25212838/) Show full description